• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Gain Therapeutics Inc (NQ: GANX )

    1.130 +0.010 (+0.89%)
    Streaming Delayed Price Updated: 10:38 AM EDT, Jul 2, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 81,163
    Open 1.200
    Bid (Size) 1.130 (33)
    Ask (Size) 1.140 (18)
    Prev. Close 1.120
    Today's Range 1.120 - 1.200
    52wk Range 1.110 - 5.330
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Pre-market stock movers are a hot topic on Friday and we're breaking down all of the latest news sending shares higher and lower! 
    Via InvestorPlace

    Performance

    YTD
    -68.83%
    -68.83%
    1 Month
    -54.25%
    -54.25%
    3 Month
    -70.50%
    -70.50%
    6 Month
    -68.83%
    -68.83%
    1 Year
    -75.22%
    -75.22%

    More News

    Read More
    Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    InvestorNewsBreaks – Gain Therapeutics Inc. (NASDAQ: GANX) Releases Pricing of Underwritten Public Offering, Projected to Reach $11M
    Via Investor Brand Network
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    S&P 500 Edges Lower; RH Shares Plunge After Q1 Results
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Gold Gains 1%; US Consumer Sentiment Falls In June
    Via Benzinga
    Dear ARM Stock Fans, Mark Your Calendars for June 24
    Via InvestorPlace
    Dow Tumbles Over 200 Points; Adobe Earnings Top Views
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Is Gain Therapeutics (GANX) Stock Down 25% Today?
    Via InvestorPlace
    Why Adobe Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Via InvestorPlace
    Gain Therapeutics Announces Pricing of $11.0 Million Public Offering
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics Announces Proposed Public Offering
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    GANX Stock Earnings: Gain Therapeutics Beats EPS for Q1 2024
    Via InvestorPlace
    Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.